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The role of autophagy in the cross-talk
between epithelial-mesenchymal
transitioned tumor cells and cancer
stem-like cells
Fabrizio Marcucci1* , Pietro Ghezzi2 and Cristiano Rumio1
Abstract
Epithelial-mesenchymal transition (EMT) and cancer stem-like cells (CSC) are becoming highly relevant targets in
anticancer drug discovery. A large body of evidence suggests that epithelial-mesenchymal transitioned tumor cells
(EMT tumor cells) and CSCs have similar functions. There is also an overlap regarding the stimuli that can induce
the generation of EMT tumor cells and CSCs. Moreover, direct evidence has been brought that EMT can give rise to
CSCs. It is unclear however, whether EMT tumor cells should be considered CSCs or if they have to undergo further
changes. In this article we summarize available evidence suggesting that, indeed, additional programs must be
engaged and we propose that macroautophagy (hereafter, autophagy) represents a key trait distinguishing CSCs
from EMT tumor cells. Thus, CSCs have often been reported to be in an autophagic state and blockade of autophagy
inhibits CSCs. On the other hand, there is ample evidence showing that EMT and autophagy are distinct events. CSCs,
however, represent, by themselves, a heterogeneous population. Thus, CSCs have been distinguished in predominantly
non-cycling and cycling CSCs, the latter representing CSCs that self-renew and replenish the pool of differentiated
tumor cells. We now suggest that the non-cycling CSC subpopulation is in an autophagic state. We propose also two
models to explain the relationship between EMT tumor cells and these two major CSC subpopulations: a branching
model in which EMT tumor cells can give rise to cycling or non-cycling CSCs, respectively, and a hierarchical model in
which EMT tumor cells are first induced to become autophagic CSCs and, subsequently, cycling CSCs. Finally, we
address the therapeutic consequences of these insights.
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Background: Epithelial-mesenchymal transition
and cancer stem-like cells
Epithelial-mesenchymal transition (EMT), i.e., the con-
version of cells with an epithelial phenotype into cells
with a mesenchymal phenotype [1, 2] involves changes
that lead to loss of cell–cell adhesion and cell polarity.
EMT is critical for embryonic development. In adults it
occurs during wound healing, tissue regeneration, organ
fibrosis, and tumor progression. Epithelial-mesenchymal
transitioned tumor cells (EMT tumor cells) have been
reported to possess increased motility and invasiveness,
tumor-propagating potential, and resistance to apoptosis
and antitumor drugs [3, 4].
CSCs are a subpopulation of tumor cells that have high
tumor-propagating potential [5], enhanced metastasis-
forming potential [6] and are resistant to antitumor drugs
[7]. There is a large overlap in the characteristics of EMT
tumor cells and CSCs also as regards the stimuli that can
induce the generation of EMT tumor cells and CSCs.
Thus, both are the result of two main events. The first
is the genetic and epigenetic instability of tumor cells
[8–12]. The second event is represented by stimuli
from the tumor microenvironment (TME) that promote
a cross-talk between different cell types within the TME
and that is largely effected by paracrine factors that are
released in response to the stimuli and interact with
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their corresponding receptors on tumor cells [13–15].
Ligand-receptor pairs like hepatocyte growth factor/c-
MET, transforming growth factor (TGF)-β/TGF-β recep-
tor, interleukin-6 (IL-6)/IL-6 receptor, platelet-derived
growth factor (PDGF)/PDGF receptor (PDGFR), epider-
mal growth factor (EGF)/EGF receptor, fibroblast growth
factor (FGF)/FGF receptor (FGFR), Gas6/AXL, WNT/
Frizzled, Hedgehog/Smoothened and Notch ligands/
Notch are examples of paracrine factors and receptors
that have been shown to promote the induction of both
EMT and CSCs [7, 15–20]. Eventually, direct evidence has
been brought showing that EMT can give rise to CSCs.
Thus, induction of EMT in immortalized human mam-
mary epithelial cells through the ectopic expression of
EMT-promoting transcription factors resulted in the
acquisition of mesenchymal traits and expression of
stem-cell markers [21]. These cells had an increased
ability to form mammospheres, a property associated
with epithelial stem cells [21]. Further demonstrating
the close linkage between EMT and CSCs, it was shown
that down-regulation of the receptor tyrosine kinase
AXL reversed EMT in human epithelial cells and breast
CSCs attenuating self-renewal and restoring chemosen-
sitivity of breast CSCs [16].
Given the multiplicity of genetic and environmental
stimuli that are at the origin of EMT and CSCs, it is not
surprising that a large number of overlapping intracellu-
lar signaling pathways have been reported to be involved
in the induction of both. Intracellular signaling hubs like
focal adhesion kinase and SRC, pathways like phosphoino-
sitide 3-kinase–AKT–mechanistic target of rapamycin,
RAF-RAS-mitogen-activated protein kinase, transcription
factors like small mother against decapentaplegic
(SMAD), nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), signal transducer and activator
of transcription (STAT) 3, and reactive oxygen species
have been shown being involved in the induction of
EMT and CSCs [7, 15, 22–26].
Given the great similarity between the functions, indu-
cing stimuli and intracellular signaling pathways of EMT
tumor cells and CSCs, and the observation that EMT
can give rise to CSCs, one is led to ask whether EMT
tumor cells are identical to CSCs. Answering this ques-
tion has considerable translational relevance, because
EMT and CSCs have become important targets in drug
discovery and several anti-EMT and anti-CSC com-
pounds are now in active clinical development [15, 27].
Main text
Differences between EMT tumor cells and CSCs
While EMT tumor cells and CSCs are induced by simi-
lar stimuli and apparently discharge similar tasks, there
is now considerable evidence suggesting that the two cell
types are distinct and may represent different stages of a
tumor cell dedifferentiation process. Thus, salinomycin,
a natural, fused polypyran ionophore, is a widely used
anti-coccidiosis agent. It was found to have anti-CSC
activity in a chemical screen designed to discover com-
pounds toxic for breast CSCs [28]. In head and neck
squamous cell carcinoma stem cells, salinomycin signifi-
cantly inhibited sphere forming-capability, repressed the
expression of CSC markers and reduced invasiveness of
CSCs [29]. On the other hand, salinomycin induced the
expression of EMT markers and decreased expression of
E-cadherin, a hallmark trait of epithelial tumor cells.
Thus, salinomycin appears to inhibit CSCs while, at the
same time, promoting EMT. Unfortunately, several differ-
ent mechanisms of action have been ascribed to salinomy-
cin and, therefore, no conclusion can be drawn as to the
signaling pathway(s) or factor(s) dictating this switch.
Other work has shown that the homeobox transcrip-
tion factor paired related homeobox 1 (Prrx1) can be
such a switch factor. Prrx1 induced EMT in cooperation
with the other transcription factor Twist1, conferring
migratory and invasive properties [30]. Loss of Prrx1, on
the other hand, was required for cancer cells to
metastasize and acquire CSC properties and markers.
Importantly, this article showed that, contrarily to com-
mon knowledge, functions of EMT tumor cells and
CSCs are not coincident. Rather, EMT tumor cells were
shown to have migratory and invasive properties, while
CSCs metastasized.
It has also been reported that tumor cell subpopula-
tions expressing a strong epithelial gene program are
enriched in highly metastatic CSCs, while subpopula-
tions with stable mesenchymal traits (i.e. EMT tumor
cells) are impoverished in CSCs, confirming that EMT
tumor cells and CSCs are functionally and phenotypic-
ally separate entities [31]. The same study showed that
both tumor cell subpopulations cooperate so that non-
metastatic cells promote the escape of metastatic cells
for metastatic colonization. These results, as well as the
previous ones, while suggesting that EMT tumor cells
and CSCs are indeed separate entities, do not exclude
the possibility that they are developmentally related.
A further turn of complexity to this picture was intro-
duced by the observation that CSCs themselves can
undergo an EMT [32]. In fact, in cell lines derived from
oral and skin carcinomas, EMT occurred within the
CD44high CSC fraction resulting in two CSC phenotypes,
one predominantly epithelial with high expression of
epithelial specific antigen (ESA), and another with EMT
tumor cell characteristics and low expression of ESA.
CSCs could switch between these two phenotypes with
EMT tumor cells being relatively quiescent [33].
A dichotomy between EMT tumor cells and CSCs has
also been confirmed in samples of different subtypes of
breast cancers from tumor patients [34]. A method for
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scoring transcriptomic EMT signatures in different types
of cancer showed that tumors of predominantly mesen-
chymal phenotype do not always show resistance to
chemotherapy and suggested that it is the CSC pheno-
type, rather than the EMT phenotype that engenders
drug resistance [35].
Overall, there is now considerable evidence that EMT
tumor cells and CSCs are neither phenotypically nor
functionally identical. Some of the reports that have
been discussed suggest even that EMT tumor cells and
CSCs are two (de)differentiation pathways that can cross
each other, but are, nevertheless, distinct. This is in ap-
parent contrast with the commonly held view that EMT
can lead to the generation of CSCs and that EMT tumor
cells and CSCs exert largely overlapping tasks.
Autophagy as a key trait that distinguishes CSCs from
EMT tumor cells
In addition to the differences that have been discussed
above, we propose that also macroautophagy (herein, au-
tophagy) [36] is a key trait that distinguishes CSCs from
EMT tumor cells. Autophagy is an adaptive catabolic
process of cells that stop dividing and enter quiescence,
and occurs in response to different forms of environ-
mental stress, including nutrient deprivation, growth
factor depletion, and hypoxia [36]. Autophagy involves
the delivery of cytoplasmic cargoes sequestered inside
double-membrane vesicles to lysosomes. Autophagosomes
are then formed and this is where the captured material is
degraded. This process of self-digestion provides nutrients
to maintain vital cellular functions during fasting and
other forms of stress. Autophagy has a suppressor role in
initial steps of tumorigenesis, but has a prosurvival effect
in established tumors by allowing tumor cells to cope with
environmental and therapy-induced stress [36].
CSCs have often been reported to be in an autophagic
state [37–39] and blockade of autophagy reduces their
activity [40] and sensitizes them to antitumor drugs [41].
Moreover, one of the most commonly used markers for
CSCs of several tumor types, CD133, promotes the
autophagocytic activity of hepatoma CSCs [42], suggesting
a functional link between CSCs and autophagy.
On the other hand, there is ample evidence that EMT
and autophagy are distinct and even mutually exclusive
events. Thus, autophagy induction impaired migration
and invasion by inhibiting EMT in glioblastoma cells
through down-regulation of the EMT-promoting tran-
scription factors Snail and Slug [43]. Vice versa, silen-
cing autophagy-inducing proteins restored the
mesenchymal phenotype [43]. The Aurora kinase A in-
hibitor alisertib induced cell cycle arrest and autophagy
and suppressed EMT in human pancreatic cancer cells
[44]. Vice versa, Aurora kinase A suppressed autophagy
and autophagic cell death by activating mechanistic in
mTOR signaling in breast cancer cells [45]. Induction of
EMT and metastasis upon inhibition of autophagy was
observed also in gastric cancer cells [46].
In several instances a molecular cross-talk between the
two pathways has been demonstrated to dictate the
choice between EMT and autophagy. Thus, suppression
of autophagy was shown to promote tumor growth and
metastasis through stabilization of the EMT-promoting
transcription factor Twist 1 by the selective autophagy
substrate p62 that accumulated due to autophagy inhib-
ition [47]. Similarly, autophagy inhibition by EMT in a
p62-dependent manner has been reported in normal
hepatocytes [48]. In metastatic breast cancer cells, the
death-effector domain-containing DNA-binding protein
(DEDD) interacted with class III phosphatidylinositol 3-
kinase (PI3KC3) to activate autophagy and attenuated
EMT [49]. DEDD physically interacted with PI3KC3 and
this led to its stabilization and activation, and autophagic
degradation of the EMT-promoting transcription factors
Snail and Twist.
Altogether, these results suggest that EMT tumor cells
and autophagic CSCs are distinct states of dedifferenti-
ation that ensue in response to similar stimuli. Autophagic
tumor cells, however, can induce other tumor cells to
undergo EMT upon release of EMT-inducing paracrine
factors [50, 51]. We suggest this to be a positive feed-back
mechanism whereby autophagic CSCs release danger sig-
nals (i.e. paracrine factors) that induce an increasing num-
ber of tumor cells to enter a state, EMT, allowing them to
cope with stress conditions in the TME. This view is con-
sistent with the knowledge that EMT is the result of a
cross-talk between tumor cells and tumor-associated cells
and is mediated by the release of paracrine factors [14].
While CSCs can be in an autophagic state that appears
to be mutually exclusive with that of EMT tumor cells,
one main function of CSCs is to self-renew and to dif-
ferentiate into mature tumor cells. This process implies
active proliferation of CSCs. When cells undergo
autophagy, however, they stop dividing and become
quiescent, a condition opposite to the previous one.
Proliferating and autophagic CSCs
There is now increasing evidence that CSCs are them-
selves heterogeneous [52–54]. Phenotypic [55] and func-
tional [56] heterogeneity of CSCs has been described.
These characteristics can change over time [57] and
differences between CSC subpopulations are not strictly
qualitative but, rather, quantitative [58]. These observa-
tions suggest that different CSC subpopulations can
switch from one to another in a dynamic manner [58].
Of particular relevance in the present context is the
observation that CSCs can be distinguished in predom-
inantly non-cycling CSCs and cycling CSCs [54, 58–60].
This is reminiscent of the proliferating and dormant
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subpopulations of somatic stem cells, with the dormant
stem cell pool representing the most primitive stem cells
[55]. Cycling CSCs are associated with cytokine produc-
tion and cytokine receptor expression and this may be
causally related with their replicative potential [61].
We propose that autophagic CSCs correspond to the
non-cycling CSC subpopulation. To this regard, in squa-
mous cell carcinoma, two CSC subpopulations have
been identified on the basis of their capacity to promote
tumor growth or invasion and metastasis, respectively.
FGFR 1 inhibition reduced tumor growth without block-
ing metastasis, whereas PDGFR α inhibition reduced
invasion and metastasis, but not tumor growth [62].
PDGFR signaling had been previously shown to induce
formation of CSCs from non-CSCs [63]. Interestingly,
PDGFR signaling has been reported to be an essential
promoter of hypoxia-induced autophagy in tumor cells
by prolonging the half-life of hypoxia-inducible factor-
1α [64]. This lends support to our view that non-cycling
CSCs are in an autophagic state.
In squamous cell carcinoma CSCs the choice between
cycling and non-cycling state is induced by TGF-β,
which bestows the properties of the non-cycling subpop-
ulation [65]. While non-responding CSCs proliferated
faster and accelerated tumor growth, TGF-β-responding
progenies invaded and showed increased protection
against anti-cancer drugs.
Regarding the functions of cycling and non-cycling
CSCs, we have already referred to reports suggesting
that the cycling subpopulation accelerates tumor growth,
while the non-cycling, possibly autophagic one, pro-
motes invasion, migration and metastasis [60, 62, 65].
Several other reports are in accordance with these re-
sults [7, 33, 66], some suggesting that the cycling sub-
population has a predominantly epithelial phenotype in
contrast to the predominantly mesenchymal phenotype
of the non-cycling subpopulation [33, 60]. Moreover,
mesenchymal-like breast CSCs were characterized as
CD24−CD44+, primarily quiescent and located at the
tumor-invasive front, whereas epithelial-like CSCs
expressed aldehyde dehydrogenase, proliferated and
were located more centrally within tumors [60].
Regarding the relationship between cycling and non-
cycling CSCs, we propose that CSCs develop into one or
the other phenotype depending on stimuli from the
TME. This view is supported by the observation that
CSCs with predominantly epithelial phenotype relied
mainly on oxygen metabolism, whereas predominantly
mesenchymal CSCs showed decreased mitochondrial
mass and membrane potential, consumed less oxygen
per cell and produced markedly reduced levels of react-
ive oxygen species, suggesting that this subpopulation
relied mainly on glycolysis for energy production [32].
Importantly, the shift towards a mesenchymal phenotype
was induced by stimuli from the TME like hypoxia or
tumor necrosis factor. These results are of interest be-
cause CSC heterogeneity may well explain the contra-
dictory results on CSC metabolism, with several reports
showing oxidative phosphorylation as the predominant
energy source, while several others show that CSCs rely
on glycolysis for energy production (see, for example,
Refs. [67, 68]).
From EMT tumor cells to CSCs: What roads are taken?
As we have already discussed, it has been shown that
EMT can give rise to CSCs [6, 21]. EMT tumor cells and
CSCs have also been reported to have similar functions,
although some results discussed above contrast this view
[30, 31]. Moreover, most recent evidence has put into
question that EMT tumor cells can metastasize [69, 70].
Yet, if we accept the view that there are two major
subpopulations of CSCs, a cycling and a non-cycling
one, then we have to address the issue as to which is the
relationship between EMT tumor cells and these CSC
subpopulations, and between the CSC subpopulations
themselves. We have proposed that cycling and non-
cycling CSCs are the result of different classes of cues
from the TME. In support, it has been demonstrated
that CSCs may display a background of genetic instabil-
ity that is similar to that of differentiated tumor cells
suggesting that, at least in some cases, environmental
cues may play the predominant, if not the sole role in
giving rise to CSCs [71]. This does not exclude, however,
that in other instances stimuli from the TME may inter-
act with a background of genetic instability. On the
other hand, we have not addressed the issue as to
whether the two subpopulations represent two consecu-
tive steps of a single developmental pathway or if they
are the result of two different developmental pathways.
Moreover, before illustrating possible models that can
accommodate acquired knowledge, it is important to
mention that both EMT tumor cells as well as CSCs can
derive from and can revert back to differentiated tumor
cells [72, 73].
Given that knowledge, we propose two models that
can explain the relationship between EMT and the two
main CSC subpopulations, non-cycling, autophagic
CSCs and cycling CSCs. We refer to the first model as
the branching model (Fig. 1a). In this model, EMT
tumor cells give rise to the cycling CSC compartment in
response to paracrine factors within a niche of the TME
that is conducive to the development of this CSC sub-
population. Alternatively, EMT tumor cells give rise to
the non-cycling, autophagic CSC compartment in re-
sponse to environmental cues that are represented by
stress conditions such as nutrient shortage, mechanical
stress, hypoxia etc. It is possible that this is a default
pathway that occurs in the absence of paracrine factors.
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EMT tumor cells that are not diverted into one of the
two pathways may remain in their state or may even re-
vert back to differentiated tumor cells.
The second, hierarchical, model (Fig. 1b) is more trad-
itional and has already been proposed for both somatic
stem cells as well as CSCs [55, 73]. Here, EMT tumor cells
are induced to become autophagic CSCs in response to
cues from the TME. Once these stimuli are relieved and/
or are replaced by paracrine factors, autophagic CSCs
become cycling (progenitor) CSCs that self-renew and re-
plenish the pool of differentiated tumor cells. Both models
foresee the possibility of bidirectional conversion, i.e. from
EMT tumor cells to CSCs and vice versa [74]. The latter
model is more consistent with a traditional view of stem
cell and CSC development and differentiation, while the
former is better apt to explain the consequences of
regional differences of the TME in giving rise to one or
the other CSC subpopulation [60].
Conclusions
In this article we reviewed the differences between EMT
tumor cells and CSCs and proposed two models to
explain the cross-talk between EMT tumor cells and two
main CSC subpopulations, one non-cycling and autoph-
agic, the other cycling. It is likely, however, that the dif-
ferences between differentiated tumor cells, EMT tumor
cells, and CSC subpopulations are not strict. Thus, it has
been demonstrated that EMT tumor cells can exist in
different transitions states, from cells with a predomin-
antly epithelial phenotype to cells with a predominantly
mesenchymal phenotype [75]. Similarly, it is conceivable
that EMT tumor cells acquire characteristics of autopha-
gic CSCs (i.e. activation of autophagy-related gene prod-
ucts) while not entirely losing those of EMT tumor cells,
and reacquire predominantly epithelial characteristics
when they develop into cycling CSCs. The phenotypic
heterogeneity of CSCs supports this possibility [55]. The
existence of phenotypic transition states would also
imply functional transition states as regards the capacity
to invade, migrate and metastasize, resist to apoptosis
and antitumor drugs, or to self-renew and differentiate
into mature tumor cells.
One key aspect that remains to be addressed concerns
the therapeutic consequences deriving from these insights.
Fig. 1 Two Models for EMT Tumor Cells Giving Rise to CSCs. a. Branching Model. In this model EMT tumor cells give rise to the cycling CSC
compartment in response to paracrine factors within a niche in the TME that is conducive to the development of this CSC subpopulation.
Alternatively, EMT tumor cells give rise to the non-cycling, autophagic CSC compartment in response to stress conditions such as nutrient
shortage, mechanical stress, hypoxia etc. It is possible that this is a default pathway occurring in the absence of paracrine factors. b. Hierarchical
Model. Here, EMT tumor cells are induced to become autophagic CSCs in response to stress conditions in the TME. Once these stimuli are
relieved and replaced or complemented by paracrine factors, autophagic CSCs become cycling CSCs that self-renew and replenish the pool
of differentiated tumor cells. CSC, cancer stem-like cell; EMT, epithelial-mesenchymal transition; TME, tumor microenvironment
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Given the heterogeneity of the tumor cell population
that encompasses differentiated tumor cells, EMT tumor
cells, and CSC subpopulations, it appears unlikely that
tumor eradication can be achieved without targeting
each of these different tumor cell populations. We
ignore, however, whether cytotoxic drugs are equally
active on differentiated tumor cells and on cycling CSCs.
Moreover, we don’t know whether anti-CSC compounds
that are in active clinical development [27], including
monoclonal antibodies against putative CSC markers
[76–78], are equally active on cycling and non-cycling
CSCs. Likewise, we don’t know whether compounds that
are potentially active on both EMT tumor cells and
CSCs are equally active on both populations and on CSC
subpopulations. Progress in these directions is war-
ranted. Nevertheless, available knowledge has allowed
for the preclinical testing of combination therapies that
target some of these tumor cell populations. For in-
stance, while curcumin has antitumor effects but, at the
same time, promotes the development of autophagic
CSCs, these cells could be depleted by targeting a CSC
marker [79]. The combination of a chemotherapeutic
drug (temozolomide) targeting cycling tumor cells with
a drug targeting quiescent tumor cells has yielded prom-
ising results in a genetically engineered mouse model of
glioblastoma [80]. Combination of a glycolytic inhibitor
targeting glioblastoma CSCs and the cytotoxic drug car-
mustine significantly impaired the sphere-forming ability
of glioblastoma CSCs in vitro and tumor formation in
vivo, leading to increase in the overall survival of mice
bearing orthotopic inoculation of glioblastoma CSCs
[81]. Other similar approaches of combination therapies
targeting different tumor cell populations, including
CSCs, have been reported [53]. Eventually, as regards
autophagic CSCs, it appears logical to test compounds
that inhibit autophagy or induce autophagic cell death in
combination with drugs that target the cycling tumor
cell compartment (mature tumor cells and cycling
CSCs). Compounds that inhibit autophagy and that are
being tested as anti-CSC compounds in clinical studies
are chloroquine or hydroxychloroquine [27, 82, 83],
while other compounds of this class are in earlier stages
of development [84].
Further preclinical and, eventually, clinical testing of
these or forthcoming combination therapies will tell us
if our increasing knowledge of EMT and CSC biology
can translate into improved therapeutic efficacy.
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